Cancer drug shows promise in keeping sarcoma in check
NCT ID NCT03793361
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether the drug regorafenib (Stivarga) could help keep metastatic soft tissue sarcoma from growing after initial chemotherapy. 127 adults whose cancer was stable or shrinking after six cycles of doxorubicin-based chemo were randomly assigned to receive either regorafenib or a placebo. The study found that regorafenib delayed cancer progression compared to placebo, suggesting it may be a useful maintenance therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
regorafenib (Stivarga)
What this could lead to
If successful, this could offer a new maintenance option to delay cancer progression in people with metastatic soft tissue sarcoma after initial chemotherapy.
What could go wrong
This is a phase 2 trial with 127 participants, so results are preliminary. Regorafenib can cause side effects like fatigue, diarrhea, and high blood pressure. The benefit in overall survival is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOFT-TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Besançon
Besançon, 25000, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Eugène Marquis
Rennes, 35042, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Georges-François LECLERC
Dijon, 21079, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre René Gauducheau
Nantes, 44805, France
-
Chu Poitiers
Poitiers, 86000, France
-
Hôpital La Timone
Marseille, 13005, France
-
Hôpitaux universitaires de Strasbourg
Strasbourg, 67000, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Curie
Paris, 75005, France
-
Institut Godinot
Reims, 51100, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut Paoli-Calmettes
Marseille, 13273, France
-
Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, 42270, France
-
Institut régional du Cancer de Montpellier
Montpellier, 34298, France